Determination of activities of human carbonic anhydrase II inhibitors from curcumin analogs by Aditama, Reza et al.
Aditama et al 
Trop J Pharm Res, April 2017; 16(4): 849  
 
Tropical Journal of Pharmaceutical Research April 2017; 16 (4): 849-854 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i4.14 
Original Research Article 
 
 
Determination of activities of human carbonic anhydrase II 
inhibitors from curcumin analogs 
 
Reza Aditama1, Yum Eryanti2, Didin Mujahidin3, Yana Maolana Syah3, Rukman 
Hertadi1* 
1Biochemistry Research Group, Faculty of Mathematics and Natural Sciences, Bandung Institute of Technology, Jalan 
Ganesha 10, Bandung 40132, 2Laboratory of Organic Synthesis, Department of Chemistry, Faculty of Mathematics and Natural 
Sciences, University of Riau, Pekanbaru, 26293, 3Organic Research Group, Faculty of Mathematics and Natural Sciences, 
Bandung Institute of Technology, Jalan Ganesha 10, Bandung 40132, Indonesia 
 
*For correspondence: Email: rukman@chem.itb.ac.id; Tel: +6281321174370 
 
Received: 2 November 2016        Revised accepted: 9 March 2017 
 
Abstract 
Purpose: To evaluate the activities of new curcumin analogs as carbonic anhydrase II (CA-II) inhibitor.  
Methods: Carbonic anhydrase II (CA-II) inhibition was determined by each ligand capability to inhibit 
the esterase activity of CA-II using 4-NPA as a substrate in 96-well plates. Dimethyl sulfoxide was used 
to dissolve each curcumin analog compound, and then diluted with biological buffer. They were then 
mixed with CA-II solution and to start the reaction, 4-NPA was added. Hydrolysis of the substrate was 
evaluated at 405 nm after incubation for 2 h at 25 °C. The IC50 value of compounds with inhibitory 
activity higher than 40 % was then evaluated. Molecular docking was also used to predict enzyme-
inhibitor interaction.  
Results: Eight new curcumin analogs were potent to inhibit CA-II activity with IC50 values ranging from 
7.92 ± 0.54 to 72.31 ± 2.21 µmol; the lowest value was exhibited by (3E,5E)-3,5-bis[(2-
hydroxyphenyl)methylidene]piperidin-4-one (a1). Molecular docking analysis revealed that this molecule 
formed hydrogen bonds with Thr199, Thr200 and Gln92 at the active site of CA-II.  
Conclusion: These curcumin analogs have inhibitory potential against CA-II; (3E, 5E)-3,5-bis[(2-
hydroxyphenyl)methylidene]piperidin-4-one (a1) has the highest inhibitory activity and  may be useful in 
the development of CA-II inhibitors for glaucoma treatment. 
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The general function of carbonic anhydrase (CA) 
is to catalyze the reversible conversion of carbon 
dioxide and water to a bicarbonate ion and a 
proton [1–3]. Misregulation of this enzyme has 
been linked to many diseases, such as 
glaucoma, cancer, and epilepsy [4,5]. The 
isozyme CA-II is known to be one of the most 
efficient in CO2 hydration [2]. Sulfonamide 
compounds, which are known as strong inhibitors 
of CA-II, have been used as commercial drugs to 
treat glaucoma [6]. However, these drugs 
produce many undesired side effects. Therefore, 
intensive search for novel drugs is ongoing, 
through synthesis of new derivatives of known 
drugs or from new molecular bases. Systematic 
search for new molecular bases is usually 
undertaken by exploring compounds from natural 
products [7,8].  
 
Curcumin and related compounds show 
promising result as a molecular base on which to 
design novel inhibitors of CA-II [9]. Due to the 
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amounts and the variety of curcuminoids from 
natural sources are limited, methods of 
synthesizing curcumin and its analogs have been 
explored [10].  
 
In the present study, 44 novel curcumin analogs, 
previously synthesized using microwave 
irradiation [10], were evaluated for their potential 
as inhibitors of human CA-II. The basic structure 




Figure 1: Basic structure of curcumin analogs 
  
 
               Table 1: List of ligand molecules 
 
Compound Structure Inhibition (%) 
a1 R1=H, R2=R2’=OH 81.44 
a2 R1=H, R2=R2’=Cl 8.89 
a3 R1=H, R2=R2’=OCH3 49.37 
a4 R1=H, R3=R3’=OH 11.43 
a5 R1=H, R3=R3’=Br 14.90 
a7 R1=H, R3=R3’=OCH3 n.a. 
a8 R1=H, R4=R4’=OH n.a. 
a9 R1=H, R4=R4’=Cl n.a. 
a10 R1=H, R4=R4’=OCH3 0.00 
a11 R1=H, R4=R4’=N(CH3)2 7.56 
a12 R1=H, R2=R3=R2’=R3’=OCH3 0.68 
a13 R1=H, R2=R5=R2’=R5’=OCH3 n.a. 
a14 R1=H, R3=R4=R3’=R4’=OCH3, 0.00 
a15 R1=H, R2=R4=R5=R2’=R4’=R5’=OCH3 0.00 
a16 R1=H, R3=R4=R5=R3’=R4’=R5’=OCH3 0.00 
b1 R1=CH3, R2= R2’=OH 0.00 
b2 R1=CH3, R2=R2’=Cl 8.02 
b3 R1=CH3, R2=R2’=OCH3 0.00 
b4 R1=CH3, R3=R3’=OH 17.71 
b6 R1=CH3, R5=R5’=Br 18.42 
b7 R1=CH3, R3=R3’=OCH3 n.a. 
b8 R1=CH3, R4= R4’=OH 3.79 
b9 R1=CH3, R4=R4’=Cl 40.60 
b10 R1=CH3, R4=R4’=OCH3 0.00 
b11 R1=CH3, R4=R4’=N(CH3)2 0.00 
b12 R1=CH3, R2=R3=R2’=R3’=OCH3 15.62 
b13 R1=CH3, R2=R5=R2’=R5’=OCH3 12.41 
b14 R1=CH3, R3=R4=R3’=R4’=OCH3 0.00 
b15 R1=CH3, R2=R4=R5=R2’=R4’=R5’=OCH3 14.85 
b16 R1=CH3, R3=R4=R5=R3’=R4’=R5’=OCH3 12.30 
c1 R1=C7H7, R2=R2’=OH 27.09 
c2 R1=C7H7, R2=R2’=Cl 22.20 
c3 R1=C7H7, R2=R2’=OCH3 0.00 
c4 R1=C7H7, R3=R3’=OH 19.09 
c6 R1=C7H7, R5=R5’=Br 40.65 
c7 R1=C7H7, R3=R3’=OCH3 48.66 
c8 R1=C7H7, R4=R4’=OH 19.09 
c9 R1=C7H7, R4=R4’=Cl 41.32 
c10 R1=C7H7, R4=R4’=OCH3 58.50 
c11 R1=C7H7, R4=R4’= N(CH3)2 0.00 
c12 R1=C7H7, R2=R3=R2’=R3’=OCH3 53.45 
c13 R1=C7H7, R2=R5=R2’=R5’=OCH3 43.25 
c14 R1=C7H7, R3=R4=R3’=R4’=OCH3 0.00 






All inhibitors were synthesized using microwave 
irradiation methods, as described in a previous 
study [10]. The side groups of each inhibitor are 
shown in 
               Table 1.  
Aditama et al 
Trop J Pharm Res, April 2017; 16(4): 851  
 
 
CA-II inhibition assay 
 
Measurement of the reduction in esterase activity 
on the substrate p-nitrophenyl acetate (4-NPA) 
was used to perform CA II inhibition assay [11]. 
The assay was divided into two sections—a pre-
test and an evaluation test. The former was 
performed to screen inhibitor molecules that 
have at least a 40 % inhibitory effect, while the 
latter was undertaken by measuring IC50 values 
for the molecules selected in the previous test.  
 
For comparison, the inhibitory activity of a 
commercial inhibitor, acetazolamide, which is 
known as a strong inhibitor of CA-II activity was 
used as standard [7,12,13]. All inhibitor samples 
were prepared by first dissolving them in 
dimethyl sulfoxide (DMSO). All inhibitor samples 
were prepared by first dissolving them in 
dimethyl sulfoxide (DMSO). To dilute the 
samples, MOPS buffer at concentration 50 mM 
(pH 6.9) was used. They were then added with 
CAII solution. Esterase activity was measured by 
adding 4-NPA substrate to the mixture and 
incubating it for 2 h at 25 C. The hydrolysis of 
the substrate was then evaluated at 405 nm 
using a Biorad Elisa Reader. The percent 
inhibition for each sample was calculated as. 
 
Inhibition (%) = {(C - T)/C}100 ………… (1) 
 
where C (i.e., control) = total enzyme activity 
without inhibitor and T (i.e., test sample) = 
activity in the presence of test compound.  
 
Inhibitory activity was expressed as IC50 values 
(the concentration at which 50 % of the enzyme 
activity inhibited), which were calculated using 
Microsoft Excel 2011 from a dose-response 
curve obtained using at least five concentrations 
(ranging from 1–10 µg/mL) of the inhibitor and 
carried out in triplicate.  
 
Molecular docking  
 
The initial structure of CA-II was obtained from 
the protein data bank (PDB), accession code 
2Q38 [14]. Redocking LSA503 to the CA-II 
crystal structure was performed to derive docking 
parameters that will be used for the docking 
simulation with curcumin analogs. All ligand 
structures were prepared by the Marvin Sketch 
program [15]. Molecular docking simulations 
were observed by Autodock Vina and a genetic 
algorithm was used for exploring ligand poses 
inside the active site of CA-II [16]. Schematic 
representations of the ligand poses and 





Measurements were carried out in triplicate and 
the results presented as mean ± SEM. Statistical 
analysis was performed by t-test using Microsoft 





CA-II inhibition  
 
In order to evaluate the potential of the 44 
curcumin analogs listed in Table 1 to inhibit CA-II 
activity, we first measured the CA-II activity in the 
absence and presence of each analog. The level 
of inhibition was expressed as the percentage 
difference in CA-II activity before and after the 
addition of the inhibitor (Table 2). Compounds 
a7, a8, a9, a10, a13, a14, a15, a16, b1, b3, b7, 
b10, b11, b14, c3, c11, c14, and c16 showed no 
inhibitory activities; compounds a2, a4, a5, a11, 
a12, b2, b4, b6, b8, b12, b13, b15, b16, c1, c2, 
c4, c8 exhibited inhibition below 40 %. Only eight  
 
    Table 2: List of ligand molecules and their inhibitory activity against CA-II 
 
Compound Inhibition (%) Compound Inhibition (%) Compound Inhibition (%) 
a1 81.44 b1 - c1 27.09 
a2 8.89 b2 8.02 c2 22.20 
a3 49.37 b3 - c3 - 
a4 11.43 b4 17.71 c4 19.09 
a5 14.90 b6 18.42 c6 40.65 
a7 - b7 - c7 48.66 
a8 - b8 3.79 c8 19.09 
a9 - b9 40.60 c9 41.32 
a10 - b10 - c10 58.50 
a11 7.56 b11 - c11 - 
a12 0.68 b12 15.62 c12 53.45 
a13 - b13 12.41 c13 43.25 
a14 - b14 - c14 - 
a15 - b15 14.85 c16 - 
a16 - b16 12.30   
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Figure 2: Schematic representation of the binding 
mode of a1 to the CA-II active site 
 
analogs exhibited inhibition levels greater than 
40 %: a1 (81.44 %), a3 (49.63 %), b9 (40.60 %), 
c7 (48.66 %), c10 (58.50 %), c6 (40.65 %), c12 
(53.45 %), and c13 (43.25 %). Therefore, only 
these eight compounds were further evaluated 
by measurement of their IC50 values.  
 
The IC50 values of these analogs ranged from 
7.92 ± 0.54 μM to 72.31 ± 2.21 μM (
    Table 2: List of ligand molecules and their inhibitory activity against CA-II 
 
Compound Inhibition (%) Compound Inhibition (%) Compound Inhibition (%) 
a1 81.44 b1 - c1 27.09 
a2 8.89 b2 8.02 c2 22.20 
a3 49.37 b3 - c3 - 
a4 11.43 b4 17.71 c4 19.09 
a5 14.90 b6 18.42 c6 40.65 
a7 - b7 - c7 48.66 
a8 - b8 3.79 c8 19.09 
a9 - b9 40.60 c9 41.32 
a10 - b10 - c10 58.50 
a11 7.56 b11 - c11 - 
a12 0.68 b12 15.62 c12 53.45 
a13 - b13 12.41 c13 43.25 
a14 - b14 - c14 - 
a15 - b15 14.85 c16 - 
a16 - b16 12.30   
 
). The compound with the lowest IC50 value, i.e., 
the most potent inhibitor among all of the 




Table 3: Inhibition of CA-II with curcumin analogs 
 
Compound IC50 (μM) 
a1 7.92±0.54 
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c12 12.37±0.78 







Molecular docking results 
 
A schematic representation of the binding mode 
of a1  to  CA-II,  as  found  during  the  molecular 




Based on the above analysis, we observed a 
correlation between the position of the hydroxyl 
group and the inhibition potential of the curcumin 
analogs. The presence of a hydroxyl group at R2 
(ortho position) in a1 molecule apparently cause 
increasing of inhibition against CA-II compared to 
the presence of hydroxyl group at R3 as in a4, b4, 
and c4; or at R4 as in a8, b8, and c8. Substitution 
of the hydroxyl group at the R2 position with more 
rigid groups, such as methoxy and benzyl 
groups, decreased the inhibitory capacity of the 
molecules. However, compounds c1 and b1 with 
a hydroxyl group at R2 exhibited contrasting 
results with a1, and both molecules showed low 
levels of inhibition towards CA-II activity. This 
suggests that the hydroxyl group may not be the 
only contributor to the inhibitory capacity of the 
curcumin analogs. Other types of interactions 
may also play roles that strengthen interactions 
with the enzyme. 
 
In order to further investigate how the a1 
molecule exhibited its strong inhibitory capacity 
against CA-II activity, we performed a molecular 
docking simulation using Autodock Vina. The 
docking result gave insight into the role of some 
of the functional groups in the a1 molecule that 
contribute to strengthening its interactions at the 
molecular level with residues inside the active 
site of the enzyme. We found that the oxygen 
atom of the hydroxyl group attached at the R2 
position of a1 strongly interacted via hydrogen 
bonding with the Thr199 and Thr200 residues 
that are located near the entrance of the active 
site cavity.  
 
Another hydrogen bond occurred between the N 
atom at the R1 position of a1 and Gln92. We 
propose that interaction of the N atom at R1 has 
a dominant effect on the inhibitory activity of CA-
II compared with the hydroxyl interaction at the 
ortho position. In addition, hydrophobic 
interactions among nonpolar moieties of the a1 
molecule with the nearest nonpolar residues also 
contributed to stabilizing the position of the a1 
molecule inside the CA-II active site. 
Interestingly, a Zn2+ ion was not directly involved 
in the stabilization of the a1 molecule, while most 
inhibitor molecules, such as the CA-II inhibitor 
acetazolamide, are strongly bound to this ion 
[12]. 
 
Previously, curcumin has been shown to inhibit 
CA-II [9]. In this study, eight new curcumin 
analogs also showed to effectively inhibit CA-II at 





The findings of this study indicate that curcumin 
analogs can be used as inhibitors of CA-II. Eight 
of the compounds demonstrated the potential to 
inhibit CA-II activity. The most effective inhibitor 
found in the present study is (3E, 5E)-3,5-bis[(2-
hydroxyphenyl) methylidene]piperidin-4-one, 
which is also supported by molecular docking 
results. This curcumin analog strongly interacts 
with the residues Thr199, Thr200 and Gln92 in 
the active site of CA-II. Thus, these findings 
show facilitate the development of novel CA-II 
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